



## Multidrug Resistance in Bacteria and New Therapeutic Options

Guest Editors:

**Dr. Gordana Maravić  
Vlahoviček**

Department of Biochemistry and  
Molecular Biology, Faculty of  
Pharmacy and Biochemistry,  
University of Zagreb, Ante  
Kovačića 1, 10000 Zagreb,  
Croatia

**Dr. Branka Bedenić**

School of Medicine, University of  
Zagreb, Šalata ul. 2, 10000  
Zagreb, Croatia

Deadline for manuscript  
submissions:

**20 May 2024**

### Message from the Guest Editors

Antimicrobial resistance presents a critical threat to public health and a great challenge to clinicians treating patients in intensive care units. Clinicians often do not have any other therapeutic option, and have to rely on antibiotic combinations in order to treat the patient. In the last few years, new antibiotics have been licenced for the treatment of infections due to CRE, CRAB and CRPA, including ceftolozan/tazobactam (CTA) ceftazidime/avibactam (CZA), imipenem/cilastatin/relebactam (IMR) and cefiderocol, as well as eravacycline, which is efficient against MRSA and VRE. The majority of these antibiotics exert good activity against KPC- and OXA-48-producing Enterobacterales and CRPA, but with the exception of cefiderocol, do not exhibit any activity against metallo-beta-lactamase-producing organisms or CRAB. Thus, the scope of this Special Issue is mostly focused on the in vitro and in vivo activity of the novel compounds for the treatment of infections associated with CRE, CRPA and CRAB.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)